Kornimate/medical-research-clean huggingface dataset:
the effects of covid-19 pandemic on the patients with fibromyalgia

Conditions: Fibromyalgia; Covid-19 Fear; Covid-19 Anxiety; Daily Life; Sleep Quality; Anxiety Depression

Summary: the investigators planned to analyze the effect of covid-19 fear and anxiety on the daily life, sleep quality and depression-anxiety levels of fibromyalgia patients.

fibromyalgia; as a chronic syndrome of unknown cause with widespread body pain, fatigue, sleep disorder, cognitive impairment and anxiety. many studies have shown a relationship between pain levels and anxiety levels in patients with fibromyalgia. covid-19 started from wuhan, china in december 2019 and spread worldwide. the rapid spread of this unexpected pandemic all over the world brought with it many conditions such as anxiety and stress disorders. it has been reported by experts that individuals with a predisposition to conditions such as anxiety and stress disorder in premorbidity require special attention.to evaluate the psychological effects of the covid-19 pandemic, the covid-19 anxiety scale was developed from lee et al. and the covid-19 fear scale was developed from ahoursou et al. the investigators planned to analyzed the effect on covid-19 fear and anxiety level on fibromyalgia patients' daily life with revised fibromyalgia impact questionnaire, sleep quality with pittsburgh sleep quality index, and anxiety-depression level with the hospital anxiety and depression scale. this study was planned as a cross-sectional case control study.

Eligibility criteria:
inclusion criteria (fibromyalgia group): * patients diagnosed as fibromyalgia syndrome according to american college of rheumatology over 1 year * patients' disease activity is stabil at least 3 months inclusion criteria (control group) patients have no physicologic or severe musculoskeletal and rheumatologic diseases exclusion criteria: * patients with having other modd disorders * patients with severe musculoskeletal diseases * patients with other rheumatologic diseases
how accurately does the diopsys visual evoked potential (vep) vision testing system detect glaucoma?

Conditions: Glaucoma Diagnosis

Summary: evaluate sensitivity and specificity of nova-dn visually evoked potentials (vep) protocol and new software method (corda) for glaucoma detection using optical coherence tomography (oct) images to differentiate between normal subjects and glaucoma suspects.

the aim of this study was to evaluate the ability of nova-dn vep protocol and corda parameters to discriminate between healthy eyes and eyes with early to moderate glaucomatous visual field loss. we will evaluate measurements of the nova-dn vep protocol, corda software and cirrus spectral domain (sd) oct software in order to compare and correlate. hypotheses is that nova-dn vep protocol and corda analysis results in a high sensitivity, specificity and area under the receiver operating characteristic (roc) curves (roc area) for glaucoma detection. second hypothesis is nova-dn vep protocol and corda parameters can differentiate between normal and glaucoma suspects.

Eligibility criteria:
inclusion criteria: group 1: healthy subjects * intraocular pressure less than 22 millimeters of mercury (mmhg) * normal appearing optic discs and retinal nerve fiber layer (rnfl) * normal optical coherence tomography (oct) rnfl thickness * normal visual field (vf) results in both eyes. group 2: glaucoma suspects * glaucomatous appearance of optic discs and/or rnfl in at least one eye * normal oct * normal vf results in both eyes. group3: glaucoma patients * glaucomatous optic disc appearance (cup to disc ratio, rim thinning or rnfl defects) * repeatable intraocular pressure (iop) of 23 mmhg or more, in at least one eye * repeatable abnormal vf tests exclusion criteria: * inability to perform reliable vf or oct * visual acuity worse than 20/40 * refractive error greater than +/-5.00 diopters sphere, greater than +/- 3.00 diopers cylinder
accuracy of cuffless ambulatory blood pressure monitors compared to cuff-based monitors in an ambulatory elderly population: a pilot study

Conditions: Hypertension

Summary: hypertension is extremely common amongst the elderly, typically manifesting as a silent disease with potentially devastating consequences if left undetected and untreated. such consequences include stroke, myocardial infarction, kidney and eye disease. opportunistic screening for hypertension is therefore standard in clinical practice. currently, the standard of care for screening in the western world is with 24-hour ambulatory cuff-based devices which are often intolerable, particularly for elderly patients. several novel cuffless wearables have been developed to overcome the limitations of cuff-based monitors. these devices offer significant advantages over cuff-based devices, including improved patient tolerance and user acceptability. numerous cuffless monitors are now commercially available. however, validation of such devices is challenging as there is no current universal standard for validating such devices.5 this is highlighted by the heterogenous and often inadequate study methods used to demonstrate accuracy of commercially available cuffless devices for blood pressure measurements. indeed, the uncertainty about their merit is reflected in international guidelines. the 2023 european society of hypertension guidelines currently do not recommend routine use of such devices in clinical practice for evaluation of blood pressure. there are limited clinical trials comparing 24-hour cuff-based devices directly to cuffless devices, and even fewer specifically in an elderly population where they may be particularly advantageous due to design features that improve tolerability. this study thus aims to address this important gap in the literature to better understand if cuffless devices provide reliable blood pressure measurements in the elderly population by directly comparing these devices to the current standard of care in blood pressure evaluation. the aktiia device will be used as a surrogate for cuffless wearables while a standard 24-hour ambulatory cuff-based device will represent cuff-based devices. the aktiia device is a cuffless solution worn as a bracelet on the wrist. it contains optical sensors which collect photoplethysmography signals from arteries in the patient's wrist and uses these to estimate blood pressure. this device is commercially available and clinically validated for use in patients up to age 85.


Eligibility criteria:
inclusion criteria: * adults \>65 years old * enrolled on sligo/leitrim icpop programme * participants (or carers) must have access to a smart phone compatible with the aktiia app exclusion criteria: * cognitive impairment or diagnosis of dementia * adults unable to provide informed consent * life-expectancy less than one year * patient's unlikely to comply with trial protocol in opinion of investigator's
precursors of cvd risk factors--project heartbeat

Conditions: Cardiovascular Diseases; Heart Diseases; Hypercholesterolemia; Hypertension

Summary: to elucidate the changes in body size, composition, and configuration occurring in adolescence, because these are important precursors of change in blood pressure and blood lipids.

background: project heartbeat! was uniquely designed to investigate the course of change in cardiovascular disease risk factors and several categories of covariates, including the anthropometric indicators addressed in this study. the data pertained to the 678 participants who entered the project in 1991-93 at ages 8, 11 or 14 years of age, of whom 49.1 percent were female and 20.1 percent were black. of the 395 participants who became eligible for 10 or more 4-monthly examinations, 349 (88.4 percent) completed at least 10 occasions; 538 participants of 556 who were eligible for seven or more examinations (96.8 percent) completed at least seven. multi-level (mln) analytic methods previously tested with other data were utilized for this analysis. design narrative: data from project heartbeat were analyzed. hypotheses tested included: (1) the time patterns of change in several indicators of body size, composition and configuration over the period of observation; (2) the relations between the time patterns of change in these indicators and the corresponding patterns for change in selected endocrine factors; and (3) the explanatory contributions of energy intake and expenditure to variation between individuals in their observed time patterns of change in these indicators. the anthropometric indicators addressed were: weight (total mass), height, body mass index (bmi, wt/ht2), fat-free mass, fat mass, per cent body fat, and fat distribution (waist/hip ratio). each of these indicators were examined first separately and then in relation to selected endocrinologic measures (testosterone, estradiol, and dheas) and to energy intake and expenditure (from interview histories of diet and physical activity). existing data from up to twelve 4-monthly examinations over the age range from 8-17 years conducted in project heartbeat! were analyzed. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
a study of pemetrexed plus carboplatin combined with radiation in patients with inoperable locally advanced non-small cell lung cancer (la-nsclc) (rt0801)

Conditions: Non-Small Cell Lung Cancer

Summary: patients with inoperable non-small-cell lung cancer will receive thoracic radiation therapy 66 gy over 33 fractions,and concurrent with 2 cycles of chemotherapy with pemetrexed (500 mg/m2,d1,repeated every 3 weeks)and carboplatin (auc=5,d1,repeated every 3 weeks).


Eligibility criteria:
inclusion criteria: * histologically proven non-small cell lung cancer (non-squamous cell carcinoma) * presence of measurable disease by recist * inoperable stage iiia or iiib * ecog performance status 0-1 * no prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy * patients must sign an informed consent indicating that they are aware of the investigational nature of the study in keeping with the policy of the hospital. exclusion criteria: * carcinoid tumor, small cell carcinoma of lung * patients with any distant metastasis * history of another malignancy within the last five years except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix any other morbidity or situation with contraindication for chemotherapy (e.g. active infection, myocardial infarction preceding 6 months, symptomatic heart disease including unstable angina, congestive heart failure or uncontrolled arrhythmias, immunosuppressive treatment) * pregnant or lactating women, women who has not taken test of pregnancy (within 14 days before the first administration) and pregnant women * women and men of childbearing potential who have no willing of employing adequate contraception

Keywords: non-small cell lung cancer pemetrexed radiation
a study in adults with cutaneous t-cell lymphoma (ctcl) retreated with brentuximab vedotin

Conditions: T-Cell Lymphoma

Summary: the main aim of this study is to describe how effective and safe the re-treatment of adults with cutaneous t-cell lymphoma (ctcl) with brentuximab vedotin is. another aim is to describe treatment patterns of persons with ctcl who have received brentuximab vedotin again. no treatment will be provided during this study. information already existing in the participants' medical charts will be reviewed and collected.

this is a non-interventional, retrospective study of participants from france, germany, spain and italy with ctcl who were retreated with brentuximab vedotin (bv) after a relapse in at least two different lines of therapy. the participants will be identified from their medical charts and those who meet the eligibility criteria will be included. the study will enroll approximately 50 participants. this multi-center trial will be conducted in europe. the participants are assessed after the last dose of bv for approximately 4 months and followed up for at least 12 months after the re-treatment.

Eligibility criteria:
inclusion criteria: * participant with a confirmed diagnosis of ctcl (including mycosis fungoides (mf), sézary syndrome (ss), primary cutaneous cd30+ anaplastic large cell lymphoma (pcalcl) and others) who reached a complete response (cr), partial response (pr) or stable disease (sd) on a previous treatment with bv and whose disease relapsed * participant who was treated with bv in at least 2 lines of therapy, other treatments could have been administered in between * participant has received three or more cycles of bv in retreatment exclusion criteria: there are no exclusion criteria for this study.

Keywords: drug therapy
impact of polymorphism on pulmonary pressure in subjects with pulmonary hypertension of different cause

Conditions: Congestive Heart Failure; Pulmonary Hypertension

Summary: pulmonary hypertension (ph) is a disease that is characterized by vasoconstriction of small vessels of the lung. many cases do have proliferation of endothelial cells within these vessels. a possible influence of polymorphisms of genes relevant for inflammatory and endothelial processes is suspected. especially patients with chronic heart failure can develope ph. the reasons therefore are lacking. the researchers investigate different polymorphism and the influence of these on pulmonary artery pressure (measured invasively) in patients with congestive heart failure (chf) and patients with primary pulmonary hypertension.

the study consists of 3 arms-patients with chf and ph, patients with chf without ph and patients without chf and ph. the ph measurement is due to routine catheterization, thereafter we measure different vasoactive polymorphism.

Eligibility criteria:
inclusion criteria: * chf with or without pulmonary hypertension or * patients with normal lvef and pulmonary hypertension * right heart catheterization due to routine * informed consent exclusion criteria: * no right heart catheterization * no informed consent * elevated pulmonary pressure due to valve diseases or congenital heart disease

Keywords: enos polymorphism tnf alpha polymorphism pulmonary pressure polymorphism of vasoactive substances
risk of shopping behavior of tapentadol immediate-release (ir) compared to oxycodone immediate-release (ir)

Conditions: Substance Abuse Detection

Summary: the purpose of this study is to compare the risk of shopping behavior of tapentadol immediate release with the risk of shopping behavior of oxycodone immediate release.

this is a retrospective (a study that looks backward in time, usually using medical records and interviews with patients) matched cohort (designated group followed or traced over a period of time) study using ims lrx database. this database covers 65% of all retail prescriptions in the united states and includes mail service and specialty pharmacy provider prescriptions independent of the method of payment. the study will include opioid naive patients exposed to tapentadol immediate release (ir) or oxycodone ir from july 2009 to december 2010. a naive patient is a patient who has not received an opioid of any type in the 3 months before the index date. the index date is the date of the first prescription for tapentadol ir or oxycodone ir after june 30, 2009. patients will be followed for 1 year from their index dates. each tapentadol ir-exposed patient will be matched to up to 4 oxycodone ir-exposed patients. matching will allow to control in the design for potential confounding variables such as time of the exposure, geographic area, specialty of the prescriber, and age. these are variables that have been related with the risk of shopping behavior or abuse.

Eligibility criteria:
inclusion criteria: * opioid naive patients (a patient who has not received an opioid of any type in the 3 months before the index date) exposed to tapentadol ir or oxycodone ir from july 2009 to december 2010 \[the index date is the date of the first prescription for tapentadol ir or oxycodone ir after june 30, 2009\] exclusion criteria: * patients with use of any opioid 3 months before the index date * patients who within 4 days on or after the index date fill a prescription for a different opioid * patients who within 4 days on or after the index date fill a prescription for the same opioid but written by a different prescriber

Keywords: substance abuse detection opioids abuse tapentadol immediate-release (ir) oxycodone immediate-release (ir)
targeted interventions for successful transition and transfer of adolescents with inborn errors of metabolism to adult services

Conditions: Transition; Inborn Errors of Metabolism

Summary: main aims of this project are * to assess the baseline status-quo of transition and "fitness for transfer" in terms of information about the adult centre and team, organisational and practical skills (blood sampling and sending, how to make an appointment etc.), disease- and treatment-related knowledge, health-related quality of life (hrqol), and self-efficacy in adolescnets with inborn errors of metabolism. biochemical or physical parameters as appropriate for the respective diseases from 12 months before are documented. * to provide targeted, structured intervention modules (using available and, if necessary, adapted materials). * to measure the effects of these interventions on information about adult services short-term (within a month) and to re-assess all other baseline status-quo parameters long-term (6 and 12 months later). psychological assessments will be complemented by biochemical or physical parameters as appropriate for the respective diseases and indicative for transition success.


Eligibility criteria:
inclusion criteria:patients * with an inborn error of metabolism in the care of a specialized metabolic care unit * requiring specialized adult metabolic care * at least 14 years old * with a disease for which at least one biochemical and / or physical parameter disease marker is well established . exclusion criteria: patients - * with insufficient knowledge of the german * with cognitive impairment to a degree that consent, and participation would be impossible * in an end-of-life situation * with a disease for which no biochemical and / or physical parameter disease marker is well established
exercise training to atrial fibrillation

Conditions: Atrial Fibrillation

Summary: to test the impacts of different exercise training programs to the cardiopulmonary function, muscle metabolism, and body mass composition

atrial fibrillation (af) has been a global threat due to its increasing incidence and prevalence, and also its potential complications of embolic stroke and heart failure, and therefore has a great impact on life expectancy and quality of life. af with preserved ventricular function is associated with exercise intolerance, and the effect of physical training had shown to improve life quality and heart function in the population. however, the optimal physical training modalities and intensities are not well studies. here we conduct a prospective, randomized, and interventional trial to investigate the effects of different exercise training programs to the burden of af. we also exploit advanced imaging modalities, including dual x-ray absorptiometry and muscle magnetic resonance, to explore the change of body mass compositions. with this project, we will be able to explore the effects of different physical exercise modalities to the burden of af and heart function, and also build up a best exercise training program, specific for this population.

Eligibility criteria:
inclusion criteria: 1. paroxysmal or persistent atrial fibrillation 2. daily activity below moderate intensity \< 300 minutes or high intensity \< 150 minutes per week. exclusion criteria: 1. active infection. 2. implant cardiac pacemaker. 3. uncontrolled hypertension. 4. cardiopulmonary contraindication to exercise training, such as decompensated heart failure, acute pulmonary edema, unstable angina, uncontrolled arrhythmia causing hemodynamic compromise, symptomatic severe aortic stenosis, suspected dissecting aortic aneurysm, severe pulmonary hypertension, acute myocarditis, endocarditis or pericarditis, uncontrolled asthma and spo2 \< 90% at rest on room air. 5. inability to follow verbal command or to walk on treadmill or use stationary bike.

Keywords: atrial fibrillation weight training aerobic training cardio-pulmonary function
a single center, prospective, case series of the treatment of pressure ulcers and decubitus ulcers.

Conditions: Pressure Ulcer

Summary: the purpose of this study is to investigate the efficacy and safety of dehydrated amnion/chorion membrane (dhacm) in the treatment of patients with stage ii or iii pressure ulcer and decubitus ulcers


Eligibility criteria:
inclusion criteria: 1. index ulcer characteristics: 1. index ulcer area after debridement is ≥ 2 cm² and ≤ 25 cm² at the randomization visit 2. ulcer must be stage ii or iii as determined by the national pressure ulcer advisory panel (npuap) pressure ulcer staging system 2. subject criteria must include: 1. age 18 or older 2. the subject or their legally authorized representative provides consent and is willing and able to participate in all procedures and follow-up evaluations necessary to complete the study exclusion criteria: 1. index ulcer characteristics that will make subject ineligible for enrollment: 1. stage i or iv ulcers as determined by npuap pressure ulcer staging system 2. signs and symptoms of local infection 3. previous surgical procedure performed at site 4. known or suspected local skin malignancy at index ulcer site 5. prior radiation therapy treatment at the index ulcer site 2. subject criteria that will make subject ineligible for enrollment: 1. presence of other diseases which, in the opinion of the investigator, may result in allograft failure or has experienced graft failure in the past (examples include: immune system disorders including systemic lupus erythematosus (sle), fibromyalgia, acquired immunodeficiency syndrome (aids) or hiv) 2. currently taking medications which in the opinion of the investigator may affect graft incorporation 3. allergy or known sensitivity to aminoglycosides such as gentamicin sulfate and/or streptomycin sulfate 4. any condition(s) that in the opinion of the investigator may seriously compromises the subject's ability to participate in this study. examples include: known history of poor adherence with medical treatment, current drug or alcohol abuse or a medical/psychiatric condition 5. pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women of childbearing potential who are planning to become pregnant during the time of the study or are unwilling/unable to use acceptable methods of contraception (birth control pills, barriers, or abstinence) 6. subjects currently enrolled in this study (i.e. concurrent enrollment in the study is prohibited) 7. subject has used any investigational drug(s) or therapeutic device(s) within 30 days preceding screening. 8. any pathology that would limit the blood supply and compromise healing 9. subject is a prisoner

Keywords: pressure ulcer, decubitus ulcer